HIF1A and cancer: In this context, the topo II-targeting effects revealed by our present study raised the notion that Q6 exerted a dual mode of action to exploit HIF-1α and topo II simultaneously, thus achieved a superior anti-cancer activity in hypoxic cancer cells.